[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"telomere-length\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:telomere-length":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,78,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100600412","avocado-consumption-and-cellular-aging-in-breast-cancer-survivors-100600412",false,"NCT07097155","Avocado Consumption and Cellular Aging in Breast Cancer Survivors","Effect of Daily Avocado Consumption on Cellular Aging in Female Breast Cancer Survivors: The ACCA Study","ACCA","Inclusion Criteria:\n\n* Women diagnosed with primary breast cancer in stages I, II or III;\n* 40-65 years old at screening;\n* Cancer treatment (radiotherapy and chemotherapy) completed ≥ 6 months but not more than 10 years at the time of recruitment;\n* Currently consuming less than 2 avocados per week;\n* Signed the informed consent letter.\n\nExclusion Criteria:\n\n* Metastasis;\n* Ductal carcinoma or lobular carcinoma in situ;\n* Breast cancer recurrence;\n* Cancer diagnosis other than breast cancer or non-melanoma skin cancer;\n* Body mass index ≥40kg\u002Fm2;\n* Currently pregnant or breastfeeding, or planning pregnancy in the following 6 months;\n* Allergy to latex;\n* Unwilling to consume avocado;\n* Immunodeficiency or HIV-positive status;\n* Alcohol abuse (\\>50g\u002Fday);\n* Unstable use of plant sterols, mineral supplements, use of fibre supplements, fish oil, or antioxidants in the 4 weeks prior to enrolment, or plans to change this during the study;\n* Currently participating in any other randomized controlled trial;\n* Difficulty or impossibility of an adequate follow-up;\n* Inability or unwillingness to give written informed consent or to communicate with study personnel, or illiteracy;\n* Patients with an acute infection or inflammation (e.g., pneumonia) will be allowed to participate in the study 3 months after recovery.","FEMALE","40 Years","65 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","Women with breast cancer are at increased risk of comorbidities and premature mortality, potentially due to accelerated biological aging. Telomere attrition has been proposed as a biomarker of this process, which could be mitigated through interventions targeting behavioral factors such as diet. In recent years, avocado has drawn attention in nutritional research due to its unique nutritional profile.\n\nMain objective: To evaluate the effect of consuming one avocado per day on biological aging-measured by telomere length-in breast cancer survivors, compared to a habitual diet (less than two avocados per week). Secondary objectives include changes in telomerase activity and biomarkers of inflammation and oxidative stress. Additional objectives include classical cardiovascular disease markers (glucose metabolism, lipid profile, blood pressure); anthropometric measurements; symptoms of depression and anxiety; quality of life and fatigue; and diet quality.\n\nMethodology: A randomized controlled parallel-group trial involving 120 breast cancer survivors. Participants will be randomly assigned to either the intervention group (one avocado per day) or the control group (habitual diet with fewer than two avocados per week) and followed for 4 months. At baseline and the end of the intervention, a general questionnaire will be administered; blood and urine samples will be collected; anthropometric and blood pressure measurements will be taken; and diet, physical activity, symptoms of depression and anxiety, quality of life, and fatigue will be assessed. Mean changes from baseline to the end of the intervention in the primary outcome (telomere length) and secondary outcomes (inflammation, oxidative stress, classical cardiovascular disease markers, anthropometric measures, symptoms of depression and anxiety, quality of life, and diet) will be compared between the intervention and control groups using linear regression models.",[28,29],"Telomere Length","Breast Cancer Females",[31,32,33],"Avocado consumption","Telomere length","Breast Cancer","RECRUITING","2026-05-07",{"date":37,"type":38},"2026-05-12","ACTUAL",{"date":40,"type":38},"2026-01-12",{"date":42,"type":22},"2027-08",{"name":44,"class":45},"Institut Investigacio Sanitaria Pere Virgili","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":46},"100572976","the-impact-of-an-evidence-based-parenting-service-on-maternal-sensitivity-and-infant-cellular-aging-in-a-population-of-under-resourced-families-100572976","NCT06740266","The Impact of an Evidence-Based Parenting Service on Maternal Sensitivity and Infant Cellular Aging in a Population of Under-Resourced Families","The Impact of Stress and Caregiver Sensitivity on Infant Cellular Aging in a Population of Under-Resourced Families: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Biological mother of infant aged 3-12 months English- or Spanish-speaking Receiving Medicaid Their infant is receiving pediatric care at WakeMed\n\nExclusion Criteria:\n\n* Experiencing an acute crisis (e.g. hospitalization, incarceration) Homeless or without stable enough housing for home visits Lacking access to a phone Previously received the Promoting First Relationships intervention",true,"18 Years",{"count":57,"type":22},250,[25],"The goal of this clinical trial study is to learn how stress in childhood, or Early Life Adversity (ELA), gets \"under the skin\" and influences long-term health. The investigators will test if the support given to parents of young children reduces childhood stress. The investigators will also test if the effects of mother's stress and Early Life Adversity can be passed down to children. Can it impact the child's long-term health? Researchers will compare the Promoting First Relationships® in Primary Care (PFR in PC) parenting program with Usual Care to see if PFR reduces mothers' stress, improves mother's sensitivity, and reduces accelerated cellular aging.\n\nParticipants will:\n\n* Be randomized to receive PFR in PC or Usual Care. PFR in PC is an evidence-based 10-week home visiting service, with 2 extra sessions at the WakeMed pediatric clinic. Usual Care is the health care and general services offered to families at the WakeMed pediatric clinic.\n* Have in-home research visits at the start of the study (Time 1, T1), about 6 months later (Time 2, T2), and 12 months later (Time 3, T3). Information collected at these visits includes:\n\n  * Answering questions about your background, past and current stress, physical and mental health, parenting behaviors, and child behavior problems (T1, T2, T3).\n  * Being videotaped doing a short teaching activity.\n  * Having a small amount of blood collected from the mother by finger prick (T1, T3).\n  * Having a small amount of blood collected from the infant by heel stick (T1, T3).",[61,62,28,63],"Parent Child Relationship","Child Social-Emotional Development","Epigenetic Aging",[65,66,67,68],"Epigenetic aging","Parenting intervention","Parent sensitivity","Pediatric setting","2026-02-04",{"date":71,"type":38},"2026-02-06",{"date":73,"type":38},"2024-12-13",{"date":75,"type":22},"2029-04",{"name":77,"class":45},"University of Washington",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":85,"minAge":55,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100608898","physical-exercise-in-patients-with-first-psychotic-episode-100608898","NCT07207538","Physical Exercise in Patients With First Psychotic Episode","Impact of Physical Exercise on Telomere Length and Other Markers of Premature Ageing in First-episode Psychosis.","Inclusion Criteria:\n\n* be at least 18 years of age\n* Having experienced a first psychotic episode in the last 3 years\n\nExclusion Criteria:\n\n* are unable to read and understand the patient information sheet and sign the informed consent form.","ALL",{"count":87,"type":22},40,[25],"Justification: Patients with first-episode psychosis are at increased risk of premature ageing and early mortality, associated with telomere shortening and increased inflammatory markers. Physical exercise has shown protective effects in the general population, but there are no intervention studies in this population.\n\nObjective: To evaluate the effect of a strength training programme on telomere length and other markers of cellular ageing in people with a first episode of psychosis.\n\nMaterial and methods: Quasi-experimental study with patients aged 18-35 years included in the PRINT programme (Salamanca). Standard treatment will be compared with standard treatment plus a 12-week strength training programme. Telomere length (qPCR), inflammatory and senescence markers (proteomics), body composition, frailty and quality of life will be analysed.\n\nApplicability: The results could support the inclusion of physical exercise programmes as a complementary intervention in early psychosis care, promoting overall health, quality of life and reducing the gap in life expectancy compared to the general population.",[28,91,92],"Exercise","First Episode Psychosis (FEP)",[91,32,94],"Aging","NOT_YET_RECRUITING","2025-10-01",{"date":98,"type":38},"2025-10-06",{"date":100,"type":22},"2026-01-01",{"date":102,"type":22},"2026-12-31",{"name":104,"class":45},"University of Salamanca",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":54,"sex":17,"minAge":55,"maxAge":112,"enrollmentInfo":113,"targetDuration":115,"studyType":116,"phases":4,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":46},"100572405","does-recombinant-fsh-rfsh-ig-gonal-f-as-compared-to-human-menopausal-gonadotrophin-hmg-affect-telomere-length-of-cumulus-cells-during-antral-follicle-growth-and-impact-blastocyst-status-100572405","NCT06732843","Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?","rFSH and hMG","Inclusion Criteria:\n\n1. Maternal age 18 - 38 years\n2. Patients requested PGT-A\n3. BMI 18- 30kg\u002Fm2\n4. Expected normoresponders\n5. Fresh autologous ejaculate (≥5 mill\u002Fml)\n6. Sperm abstinence: 2-3 days\n7. Normal female\u002Fmale karyotype\n8. Regular menstrual cycle length: 25-32 days\n9. AFC of 5-10 in each ovary at the beginning of the stimulation\n10. Trigger: dual trigger: 2.500 IU urinary hCG + 0.3 mg Decapeptyl. (13)\n11. A wash-out period between 1 to 3 months; an inter-cycle variation of 10% in AFC, measured by the same physician, is accepted.\n12. Couple agrees to perform two stimulations before continuing with embryo transfer\n\nExclusion Criteria:\n\n* 1\\. Uterine abnormalities as diagnosed by ultrasound 2. Any hormonal or oral contraceptive pretreatment of 3 months preceding the treatment 3. Endometriosis according to American Fertility Society (AFS) ≥3 4. ≥ 2 miscarriages 5. Bologna criteria poor responders (14)","38 Years",{"count":114,"type":22},10,"60 Months","OBSERVATIONAL","Gonal-F® (follitropin alfa) is a recombinant FSH without LH activity, while Menopur® contains both LH and hCG. The MEGASET trial compared Menopur® and Gonal-F® in GnRH antagonist cycles with SET, showing similar efficacy. A subsequent study (MEGASET-HR) in high responders found ongoing pregnancy rates of 35.5% for Menopur® and 30.7% for Gonal-F®, with a lower early pregnancy loss for Menopur® (14.5% vs 25.5%).\n\nTelomere length (TL) in oocyte cumulus cells (CC) correlates with oocyte quality and embryo outcomes. This study aims to assess whether stimulation type (hMG vs. Gonal-F) affects TL in CC and subsequent blastocyst development. A randomized, open-label, cross-over study in normo-responders will analyze telomere length, embryo quality, and hormonal markers.",[119,28,120],"OVARIAN STIMULATION","Telomere Length, Mean Leukocyte",[122,123,124,125,126,127,128,129,130,131],"recombinant human follicle-stimulating hormone (rFSH)","uman-menopausal-gonadotropin (hMG","ocyte quality","embryo quality","blastocyst development","Menopur","GonalF","GnRH antagonist cycles","trophectoderm","cumulus cells","2025-07-24",{"date":134,"type":38},"2025-07-25",{"date":136,"type":38},"2025-07-23",{"date":138,"type":22},"2027-07-31",{"name":140,"class":45},"ART Fertility Clinics LLC"]